To the Editor As reported by Dr Aronne and colleagues,1 tirzepatide demonstrates therapeutic benefits in weight loss; adults with obesity completing the 36-week lead-in period of the trial experienced a mean weight reduction of 20.9%. From randomization at week 36, those who switched to receiving placebo had a 14% weight regain, while those continuing tirzepatide achieved an additional 5.5% weight reduction during the 52-week double-blind period. However, we have several concerns.